Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04243616
Title Cemiplimab in High Risk or Locally Advanced Hormone Receptor Positive HER2 Negative or Triple-Negative Breast Cancer
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Medical College of Wisconsin
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.